13 results about "Ventricular dysrhythmia" patented technology

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

The application discloses a nuciferine derivative, a preparation method and application thereof, and relates to the technical field of medicines.The application provides a nuciferine derivative, and further provides a preparation method of the nuciferine derivative.The nuciferine derivative provided by the application greatly improves the treatment effect of arrhythmia, reduces the adverse reaction of the drug, and reduces the risk of inducing ventricular arrhythmia; in addition, the raw material is cheap and easy to obtain, the production cost is greatly reduced, the nuciferine derivative is suitable for large-scale production, and the nuciferine derivative has a certain treatment effect on QT syndrome, and has a wide application prospect in the preparation of drugs for resisting arrhythmia and treating QT syndrome.

The application belongs to the field of heart disease treatment and natural medicine compound, and provides application of bufalin or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating reperfusion arrhythmia. Experiments in vitro and in vivo prove that bufalin inhibits L-type calcium channels in a concentration-dependent manner, reduces extracellular calcium ion inflow, and further reduces the incidence of ventricular arrhythmia, arrhythmia, reduces ventricular conduction time, increases left ventricular conduction velocity, and reduces ventricular conduction dispersion; and provides a new drug selection for the treatment of reperfusion arrhythmia.

A method of improving electrical conduction across an impaired region of a tissue (e.g., myocardial tissue), includes applying an electrically conductive wiring (e.g., carbon nanotube fibers) across the impaired region. The electrically conductive wiring can become associated with non-impaired regions of the tissue on opposite sides of the impaired region by suturing. The method can also be utilized to treat or prevent cardiac arrhythmia in a subject (e.g., ventricular arrhythmia). The electrically conductive wiring includes carbon nanotubes, such as carbon nanotube fibers. Such electrically conductive wiring can be used to transmit electrical signals to a tissue or sense electrical signals from the tissue. Suture threads including carbon nanotubes, such as carbon nanotube fibers, are provided.

The present disclosure relates to compositions and methods, including prodrugs of (S)-sec-butyl 2-(3-(4-(2- (diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl) acetate that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, ventricular arrhythmias, or ventricular fibrillation.

The invention belongs to the technical field of medical treatment, and provides a method for predicting long-term relapse of early ventricular ablation based on intracardiac potential spectrums.The method comprises the steps that intracardiac bipolar potentials before and after ablation are collected at a successful ablation target; performing fast Fourier transform on the potential signal to obtain a power frequency spectrum of the potential signal; in the 0-200Hz analysis frequency band, calculating the area under the curve of the 50-200Hz high-frequency component as the integral of the high-frequency component, and calculating the ratio of the integral of the high-frequency component to the total integral of the frequency spectrum to obtain the integral ratio of the high-frequency component; the ratio before ablation and after ablation is calculated respectively, the change value of the ratio is calculated and determined through ROC curve analysis, and the change value exceeding a threshold value is used as a critical value for predicting the low recurrence risk after ablation, time-domain signal analysis is innovated into frequency-domain quantitative analysis, an objective and accurate new index is provided for evaluating the ablation injury quality and predicting prognosis, and the risk of low recurrence after ablation is predicted. The device is especially suitable for ventricular arrhythmia of aorta root origin.

The application discloses a kind of for preventing or treating post myocardial infarction ventricular arrhythmia pharmaceutical composition, the pharmaceutical composition is by everolimus, ethmolam and fluoxetine, belongs to the field of medicine technology.Immunoblotting proves that everolimus, ethmolam and fluoxetine can inhibit fatty acid oxidation protein.In vitro and in vitro cardiac electrophysiology experiment proves that the pharmaceutical composition can effectively reduce post myocardial infarction ventricular arrhythmia susceptibility.TTC staining proves that the pharmaceutical composition can effectively reduce post myocardial infarction myocardial damage area.Based on the above composition in the regulation of post myocardial infarction ventricular arrhythmia susceptibility, it can be further developed in the clinical application of the disease.

The invention relates to the field of medicine, in particular to a biomarker for diagnosis and prognosis evaluation of ventricular arrhythmia of a patient with dilated cardiomyopathy (DCM) and application of the biomarker. Matrix metalloproteinase-9 (MMP-9), 5-hydroxytryptamine (5-HT), noradrenaline (NE) and acetylcholine (ACh) are screened to serve as a biomarker combination, and by measuring the levels of MMP-9, 5-HT, NE and ACh in plasma, whether a DCM patient is accompanied with ventricular arrhythmia or not can be effectively recognized, the severity of the condition of the patient is evaluated, and the prognosis risk of the patient is predicted. The synergistic effect of MMP-9, 5-HT, NE and ACh can complement the defects of a single index, the diagnosis efficiency is improved, particularly, high specificity is achieved for ventricular arrhythmia, and an important basis is provided for risk stratification and individualized treatment of DCM patients.

A medical device system, such as an extra-cardiovascular implantable cardioverter defibrillator ICD, senses R-waves from a first cardiac electrical signal by a first sensing channel and stores a time segment of a second cardiac electrical signal in response to each sensed R-wave. The medical device system determines a morphology parameter correlated to signal noise from time segments of the second cardiac electrical signal, detects a noisy signal segment based on the signal morphology parameter; and withholds detection of a tachyarrhythmia episode in response to detecting a threshold number of noisy signal segments.

The invention discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial infarction, and belongs to the technical field of medicines. The pharmaceutical composition is prepared from everolimus, etomadectin and fluoxetine. Western blot proves that everolimus, etomadectin and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro cardiac electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the ventricular arrhythmia susceptibility after myocardial infarction. TTC dyeing proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial infarction. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial infarction, the clinical application of the composition to the ventricular arrhythmia after myocardial infarction can be further developed.

The application belongs to the field of heart disease treatment and natural medicine compound, and provides application of bufalin or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating reperfusion arrhythmia. Experiments in vitro and in vivo prove that bufalin inhibits L-type calcium channels in a concentration-dependent manner, reduces extracellular calcium ion inflow, and further reduces the incidence of ventricular arrhythmia, arrhythmia, reduces ventricular conduction time, increases left ventricular conduction velocity, and reduces ventricular conduction dispersion; and provides a new drug selection for the treatment of reperfusion arrhythmia.

The invention belongs to the technical field of medicines, and discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial ischemia-reperfusion, the pharmaceutical composition is composed of diosmin, etomoxazide and fluoxetine, and the mass ratio of diosmin to etomoxazide to fluoxetine is 1: 1: 1. Western blot proves that diosmin, etomagazide and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro heart electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion. TTC staining proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial ischemia reperfusion. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion, the clinical application of the composition to the ventricular arrhythmia after myocardial ischemia-reperfusion can be further developed.

The invention relates to the technical field of time series data processing, in particular to a self-supervised ventricular arrhythmia anomaly detection method and system based on double-domain knowledge distillation, and the method comprises the steps: constructing a three-classification task sample data set based on normal electrocardiogram data, pseudo noise data and pseudo abnormal electrocardiogram data; a time-frequency domain double-branch processing model architecture is constructed, each processing branch is composed of an encoder and a classification head, the time-frequency domain double-branch processing architecture serves as a student model, a teacher model of the same structure is constructed based on the time-frequency domain double-branch processing architecture, and a classification task is constructed in the teacher model through normal data and two kinds of pseudo-abnormal data. The ability of an encoder as a student to discriminate noise data and ventricular arrhythmia data is enhanced in unsupervised training through offline knowledge distillation. According to the method, the accuracy of ventricular arrhythmia anomaly detection and the noise discrimination capability of the model can be effectively improved, and the false alarm rate is reduced.